GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lumos Diagnostics Holdings LDX.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.07

+21.67%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$12.4m

FY2018FY2025

Net income

−$7.2m

FY2018FY2025

Free cash flow

−$9.4m

FY2018FY2025

Shareholders' equity

$6.2m

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue$12.4m$11.1m$10.5m$11.6m$18.9m$5.6m$4.4m$1.8m
Gross profit$7.8m$7.1m$6.0m$4.5m$8.6m$2.4m$2.0m$781,200
Research and development$106,000$69,000$421,000$1.3m$1.2m$1.9m$563,100$172,400
Operating income−$6.2m−$6.7m−$9.1m−$23.6m−$10.8m−$8.6m−$2.8m−$1.2m
Net income−$7.2m−$8.6m−$9.0m−$45.7m−$15.0m−$9.0m−$4.5m−$1.2m
Diluted earnings per share-0.01-0.02-0.04-0.20-0.10-0.06-0.03-0.01

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets$20.8m$26.8m$25.4m$36.9m$98.0m$29.5m$24.9m$8.3m
Cash and short-term investments$2.0m$6.5m$3.0m$8.0m$44.9m$830,400$3.0m$226,400
Total liabilities$14.7m$19.7m$15.9m$19.1m$39.7m$7.9m$13.5m$5.5m
Debt$7.0m$8.1m$9.8m$7.2m$8.0m$4.0m$10.2m$4.8m
Shareholders' equity$6.2m$7.1m$9.5m$17.9m$58.3m$21.6m$11.4m$2.8m
Shares outstanding680m494m250m224m150m160m160m160m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−$9.3m$946,000−$9.6m−$18.0m−$10.9m−$3.8m−$3.0m−$268,700
Capital spending−$53,000−$98,000−$155,000−$4.4m−$8.3m−$6.5m−$2.5m−$1.6m
Free cash flow−$9.4m$848,000−$9.8m−$22.4m−$19.2m−$10.3m−$5.5m−$1.8m

Latest quarters

By quarter end

Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022Jun 2022
Revenue$6.1m$6.1m$6.3m$8.4m$2.8m$5.5m$5.1m$6.4m
Gross profit$4.2m$3.6m$4.2m$5.7m$1.4m$3.5m$2.5m$2.1m
Operating income−$4.1m−$3.7m−$2.5m−$1.2m−$5.5m−$3.3m−$5.8m−$12.7m
Net income−$4.9m−$4.4m−$2.8m−$2.2m−$6.4m−$2.4m−$6.6m−$34.6m
Diluted earnings per share-0.01-0.01-0.00-0.00-0.01-0.01-0.03-0.13
Cash from operations—−$3.0m−$6.0m$5.0m−$4.0m−$3.0m−$5.0m−$6.0m
Capital spending———————−$1.0m
Free cash flow———————−$7.0m
Total assets$21.1m$20.8m$26.5m$26.8m$23.1m$25.4m$25.0m$36.9m
Cash and short-term investments$3.0m$2.0m$5.5m$6.5m$1.4m$3.0m$780,000$8.0m
Debt$5.4m$5.9m$6.8m$7.1m$7.6m$9.1m$4.2m$6.2m
Shareholders' equity$5.2m$6.2m$9.8m$7.1m$9.2m$9.5m$10.9m$17.9m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue2.2%17.0%—
Operating income-35.9%-6.3%—
Net income-46.0%-4.5%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin63.3%55.4%51.8%—
Operating margin-54.9%-99.9%-92.7%—
Net margin-67.0%-154.2%-134.7%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-19.0-1.4-1.4-0.1-0.8
Price to sales11.01.11.20.40.6

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.